Confo Therapeutics Announces EUR 60M Series B Financing to Advance Pipeline of Novel GPCR-Modulating Therapies into Clinical Development

  • Proceeds to support Phase 1 clinical trials for two proprietary programs, and to advance two additional programs to IND approval
  • Company to expand R&D efforts to discover additional development candidates for rare endocrine diseases and obesity, including those targeting Class B GPCRs
  • Portfolio expansion to include a focus on agonistic GPCR antibodies

Ghent, Belgium – July 26, 2024 – Confo Therapeutics, a clinical-stage company and leader in the discovery of medicines targeting G-protein coupled receptors (GPCRs), today announced the closing of a EUR 60M Series B financing. The round was led by Ackermans & van Haaren (AvH) and included participation from additional new investors, Driehaus Capital Management and Quest for Growth (QfG), as well as existing investors, BioGeneration Ventures (BGV), Capricorn Health-tech Fund (CHF), Fund+, MINTS (University of Michigan), Perceptive Advisors, Qbic, PMV, V-Bio Ventures, VIB and Wellington Partners.

The proceeds will be used to advance two, wholly owned programs through Phase 1 and two additional programs to IND approval, including molecules targeting GPR75 for obesity. Confo will expand its portfolio of GPCR-targeting small molecules and therapeutic antibodies, which includes an emphasis on agonistic antibodies.

“With the support from our experienced international investor syndicate, we plan to accelerate our ambitious development pipeline,” said Cedric Ververken, CEO of Confo Therapeutics. “Our plans include potential new therapies for severe rare endocrine diseases, as well as next-generation obesity drugs which could be used in combination with, or as an alternative to, GLP-1R agonists.”

Jeroen Vangindertael, Investment Manager at AvH added: “We have followed Confo’s development and have been repeatedly impressed with Confo’s proprietary platform and its experienced team, as well as their strategy for novel treatments in obesity and rare endocrine disorders. We are especially excited by the remarkable ease with which Confo can discover agonistic antibodies directed to GPCRs, opening up a new route to generating novel medicines. We feel privileged to contribute to the mission of Confo Therapeutics and its exceptional management team together with this syndicate of specialist life science investors.”

As part of the Series B financing round, Dr. Vangindertael will join Confo’s Board of Directors, and Mr. Alex Munns, Assistant Portfolio Manager at Driehaus, will be appointed as Board Observer.

“I am delighted to welcome our new investors and thank them for their support as we enter our next phase of development,” said Dieter Weinand, Independent Chairman of the Board of Confo Therapeutics. “In combination with the continued backing of our existing investors, the team will be able to focus on advancing these therapeutic candidates to benefit patients living with metabolic and endocrine disorders.”

For more information, please contact:

Confo Therapeutics

Dr. Cedric Ververken, CEO

+ 32 (0) 9 396 74 00

info@confotherapeutics.com

Trophic Communications

Valeria Fisher or Desmond James

+49 (0) 175 8041816 or +49 (0) 1516 7859086

Email: confo@trophic.eu

About Confo Therapeutics

Confo Therapeutics is a clinical-stage biotechnology company committed to identifying and accelerating novel medicines targeting GPCRs (G protein-coupled receptors). It discovers small molecules and antibodies with the desired pharmacology by employing its proprietary discovery platform which uses conformation-specific ConfoBodies® to promote GPCRs into functionally relevant states. Using its platform, the company is building a pipeline of product candidates to transform therapeutic outcomes for patients with a focus on metabolic and endocrine diseases. The Company’s mission is being advanced by a team of highly experienced industry experts with extensive knowledge of the discovery and development of GPCR-directed medicines. Confo Therapeutics is headquartered in Ghent, Belgium. For more information, visit www.confotherapeutics.com

 

 

 

 

Share

Latest stories

Website preview
Spectacular Breakthrough in Sepsis Research: Vitamin B1 Stops Deadly Lactate Production and Opens the Door to a New Treatment
Ghent, July 29, 2025 – Scientists in Ghent have achieved a major breakthrough in sepsis research. In a study on mice, the researchers demonstrate that vitamin B1 (thiamine pyrophosphate, TPP) restores mitochondrial energy metabolism, drastically reduces lactate production, and increases survival rates in sepsis. The study results were published in Cell Reports.
press.vib.be
Website preview
Scientists discover brain switch that controls freeze-or-flight survival instincts
Leuven, Belgium, 23 July 2025 – Researchers have identified a key neural switch that controls whether animals instinctively flee from a threat or freeze in place. By comparing two closely related deer-mouse species, they found that this switch is calibrated by evolution to match the animal's habitat. This neural circuit is hypersensitive in mice living in densely vegetated environments, causing instant escape, but less responsive in their open-field cousins, who are more likely to freeze. In doing so, the research team uncovered an important way in which evolution fine-tunes the brain for survival.
press.vib.be
Website preview
Groundbreaking Study Offers a Novel Approach to Enhance Neuromuscular Function in Patients with Duchenne Muscular Dystrophy
Findings published in The American Journal of Pathology identify GLUD1 enzyme as a potential therapeutic target for muscle restoration through metabolic reprogramming, addressing clinically unmet need for treatment beyond symptom relief
press.vib.be

About VIB

VIB is an independent research institute that translates insights in biology into impactful innovations for society. Collaborating with the five Flemish universities, it conducts research in plant biology, cancer, neuroscience, microbiology, inflammatory diseases, artificial intelligence and more. VIB connects science with entrepreneurship and stimulates the growth of the Flemish biotech ecosystem. The institute contributes to solutions for societal challenges such as new methods for diagnostics and treatments, as well as innovations for agriculture. 

Learn more at www.vib.be.

Contact

Suzanne Tassierstraat 1 9052 Zwijnaarde

+32 9 244 66 11

press@vib.be

vib.be